Taken together with our observation of decreased DNAM-1 and NKG2D expression on tumor-infiltrating NK cells in sarcoma and the enhanced cytotoxic activity of NK-92 cells expressing DNAM-1 or NKG2D against sarcoma explants, these results put forward DNAM-1- or NKG2D-based immunotherapy as a potentially effective approach in sarcoma treatment. The gene discussed is KLRK1; the disease is sarcoma.